trv734 trv734 trv734 is a drug developed by trevena inc which acts as a biased agonist at the μ-opioid receptor, selective for activation of the g-protein signalling pathway over β-arrestin 2 recruitment. it is closely related to oliceridine and has a similar pharmacological profile, but unlike oliceridine which has to be injected, trv734 is suitable to be administered orally. trv734identifiers iupac name n--2-decan-9-yl]ethanamine pubchem cid72695064chemical and physical dataformulac22h28fn3omolar mass369.484 g·mol−13d model (jsmol)interactive image smiles c1ccc2(c1)c(cco2)(ccncc3=cc(=cn=c3)f)c4=cc=cc=n4 inchi inchi=1s/c22h28fn3o/c23-19-13-18(15-25-16-19)14-24-11-8-21(20-5-1-4-10-26-20)9-12-27-22(17-21)6-2-3-7-22/h1,4-5,10,13,15-16,24h,2-3,6-9,11-12,14,17h2/t21-/m1/s1key:crkvmjhrolsfmv-oaqylsrusa-n